Training in Transplantation and Cellular Therapy in Latin America: A Cross-Sectional Study of the LABMT: Cell Therapy and Transplantation Training in Latin America: A LABMT Survey.


Journal

Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629

Informations de publication

Date de publication:
10 Oct 2024
Historique:
received: 09 07 2024
revised: 11 09 2024
accepted: 27 09 2024
medline: 13 10 2024
pubmed: 13 10 2024
entrez: 12 10 2024
Statut: aheadofprint

Résumé

Hematopoietic cell transplantation (HCT) is a complex and resource-intensive procedure that has become a critical treatment for certain hematologic conditions. However, in Latin America, access to HCT is limited compared to high-income countries, in part due to a lack of standardized training programs for HCT professionals. To address this gap, the Latin-American Bone Marrow Transplantation Group (LABMT) conducted a cross-sectional study to assess the current state of training programs in HCT and cellular therapy across the region. This study aimed to describe and analyze the availability, characteristics, and challenges of HCT training programs in Latin America, with a focus on identifying barriers and proposing solutions for improvement. A cross-sectional survey was sent to 127 recognized HCT centers across 14 Latin American countries in December 2022. The survey collected data on institutional characteristics, training program structure, costs, and barriers to program development. Descriptive statistics were used to summarize the data, and comparative analyses were performed using Chi-square and Mann-Whitney tests. Of the 127 centers surveyed, 50 (39%) responded, with the majority located in Brazil (34%) and Mexico (30%). Among the respondents, 64% (n=32) offered formal training programs lasting six months or longer. The most significant barriers reported were lack of funding (n=21), limited number of transplant procedures (n=15), and a shortage of qualified professors (n=11). Proposed solutions included increasing student mobility opportunities (n=28), enhancing program quality (n=27), and improving access to funding (n=15). Only 6% of programs offered exposure to CAR-T therapy, and fewer than half of the centers provided international rotations. This study highlights significant disparities in HCT training programs across Latin America, with most countries lacking access to formalized training. While Brazil and Mexico serve as regional hubs, other nations have limited or no training opportunities. Addressing these gaps through increased funding, international collaborations, and standardized curricula is essential to improving HCT training and ultimately patient care in the region.

Sections du résumé

BACKGROUND BACKGROUND
Hematopoietic cell transplantation (HCT) is a complex and resource-intensive procedure that has become a critical treatment for certain hematologic conditions. However, in Latin America, access to HCT is limited compared to high-income countries, in part due to a lack of standardized training programs for HCT professionals. To address this gap, the Latin-American Bone Marrow Transplantation Group (LABMT) conducted a cross-sectional study to assess the current state of training programs in HCT and cellular therapy across the region.
OBJECTIVE(S) OBJECTIVE
This study aimed to describe and analyze the availability, characteristics, and challenges of HCT training programs in Latin America, with a focus on identifying barriers and proposing solutions for improvement.
STUDY DESIGN METHODS
A cross-sectional survey was sent to 127 recognized HCT centers across 14 Latin American countries in December 2022. The survey collected data on institutional characteristics, training program structure, costs, and barriers to program development. Descriptive statistics were used to summarize the data, and comparative analyses were performed using Chi-square and Mann-Whitney tests.
RESULTS RESULTS
Of the 127 centers surveyed, 50 (39%) responded, with the majority located in Brazil (34%) and Mexico (30%). Among the respondents, 64% (n=32) offered formal training programs lasting six months or longer. The most significant barriers reported were lack of funding (n=21), limited number of transplant procedures (n=15), and a shortage of qualified professors (n=11). Proposed solutions included increasing student mobility opportunities (n=28), enhancing program quality (n=27), and improving access to funding (n=15). Only 6% of programs offered exposure to CAR-T therapy, and fewer than half of the centers provided international rotations.
CONCLUSIONS CONCLUSIONS
This study highlights significant disparities in HCT training programs across Latin America, with most countries lacking access to formalized training. While Brazil and Mexico serve as regional hubs, other nations have limited or no training opportunities. Addressing these gaps through increased funding, international collaborations, and standardized curricula is essential to improving HCT training and ultimately patient care in the region.

Identifiants

pubmed: 39395713
pii: S2666-6367(24)00694-8
doi: 10.1016/j.jtct.2024.09.025
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest None

Auteurs

Andrés Noyola-Pérez (A)

Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González. Monterrey, México; Hospital de Clínicas, Curitiba, Brazil; Universidad Autónoma de Baja California, Facultad de Medicina. Mexicali, México; Unidad de Trasplante Dr. Abraham Sumoza, Valencia, Venezuela; Hospital Central. Instituto de Previsión Social, Asunción, Paraguay; Hospital Pequeño Principe, Curitiba, Brazil; Hospital Británico, Montevideo Uruguay; Favaloro, University Hospital, Buenos Aires, Argentina; ITAC, Buenos Aires, Argentina; Instituto de Cancerología, Las Américas, Medellín, Colombia.

Rafaella Ribas-Muratori (R)

Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González. Monterrey, México; Hospital de Clínicas, Curitiba, Brazil; Universidad Autónoma de Baja California, Facultad de Medicina. Mexicali, México; Unidad de Trasplante Dr. Abraham Sumoza, Valencia, Venezuela; Hospital Central. Instituto de Previsión Social, Asunción, Paraguay; Hospital Pequeño Principe, Curitiba, Brazil; Hospital Británico, Montevideo Uruguay; Favaloro, University Hospital, Buenos Aires, Argentina; ITAC, Buenos Aires, Argentina; Instituto de Cancerología, Las Américas, Medellín, Colombia.

Marco A Vargas-Hernández (MA)

Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González. Monterrey, México; Hospital de Clínicas, Curitiba, Brazil; Universidad Autónoma de Baja California, Facultad de Medicina. Mexicali, México; Unidad de Trasplante Dr. Abraham Sumoza, Valencia, Venezuela; Hospital Central. Instituto de Previsión Social, Asunción, Paraguay; Hospital Pequeño Principe, Curitiba, Brazil; Hospital Británico, Montevideo Uruguay; Favaloro, University Hospital, Buenos Aires, Argentina; ITAC, Buenos Aires, Argentina; Instituto de Cancerología, Las Américas, Medellín, Colombia.

Laura Saavedra-Salazar (L)

Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González. Monterrey, México; Hospital de Clínicas, Curitiba, Brazil; Universidad Autónoma de Baja California, Facultad de Medicina. Mexicali, México; Unidad de Trasplante Dr. Abraham Sumoza, Valencia, Venezuela; Hospital Central. Instituto de Previsión Social, Asunción, Paraguay; Hospital Pequeño Principe, Curitiba, Brazil; Hospital Británico, Montevideo Uruguay; Favaloro, University Hospital, Buenos Aires, Argentina; ITAC, Buenos Aires, Argentina; Instituto de Cancerología, Las Américas, Medellín, Colombia.

Cristóbal Frutos (C)

Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González. Monterrey, México; Hospital de Clínicas, Curitiba, Brazil; Universidad Autónoma de Baja California, Facultad de Medicina. Mexicali, México; Unidad de Trasplante Dr. Abraham Sumoza, Valencia, Venezuela; Hospital Central. Instituto de Previsión Social, Asunción, Paraguay; Hospital Pequeño Principe, Curitiba, Brazil; Hospital Británico, Montevideo Uruguay; Favaloro, University Hospital, Buenos Aires, Argentina; ITAC, Buenos Aires, Argentina; Instituto de Cancerología, Las Américas, Medellín, Colombia.

Carmem Bonfim (C)

Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González. Monterrey, México; Hospital de Clínicas, Curitiba, Brazil; Universidad Autónoma de Baja California, Facultad de Medicina. Mexicali, México; Unidad de Trasplante Dr. Abraham Sumoza, Valencia, Venezuela; Hospital Central. Instituto de Previsión Social, Asunción, Paraguay; Hospital Pequeño Principe, Curitiba, Brazil; Hospital Británico, Montevideo Uruguay; Favaloro, University Hospital, Buenos Aires, Argentina; ITAC, Buenos Aires, Argentina; Instituto de Cancerología, Las Américas, Medellín, Colombia.

Fernando Barroso-Duarte (F)

Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González. Monterrey, México; Hospital de Clínicas, Curitiba, Brazil; Universidad Autónoma de Baja California, Facultad de Medicina. Mexicali, México; Unidad de Trasplante Dr. Abraham Sumoza, Valencia, Venezuela; Hospital Central. Instituto de Previsión Social, Asunción, Paraguay; Hospital Pequeño Principe, Curitiba, Brazil; Hospital Británico, Montevideo Uruguay; Favaloro, University Hospital, Buenos Aires, Argentina; ITAC, Buenos Aires, Argentina; Instituto de Cancerología, Las Américas, Medellín, Colombia.

Sebastián Galeano (S)

Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González. Monterrey, México; Hospital de Clínicas, Curitiba, Brazil; Universidad Autónoma de Baja California, Facultad de Medicina. Mexicali, México; Unidad de Trasplante Dr. Abraham Sumoza, Valencia, Venezuela; Hospital Central. Instituto de Previsión Social, Asunción, Paraguay; Hospital Pequeño Principe, Curitiba, Brazil; Hospital Británico, Montevideo Uruguay; Favaloro, University Hospital, Buenos Aires, Argentina; ITAC, Buenos Aires, Argentina; Instituto de Cancerología, Las Américas, Medellín, Colombia.

Gregorio Jaimovich (G)

Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González. Monterrey, México; Hospital de Clínicas, Curitiba, Brazil; Universidad Autónoma de Baja California, Facultad de Medicina. Mexicali, México; Unidad de Trasplante Dr. Abraham Sumoza, Valencia, Venezuela; Hospital Central. Instituto de Previsión Social, Asunción, Paraguay; Hospital Pequeño Principe, Curitiba, Brazil; Hospital Británico, Montevideo Uruguay; Favaloro, University Hospital, Buenos Aires, Argentina; ITAC, Buenos Aires, Argentina; Instituto de Cancerología, Las Américas, Medellín, Colombia.

Amado Karduss (A)

Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González. Monterrey, México; Hospital de Clínicas, Curitiba, Brazil; Universidad Autónoma de Baja California, Facultad de Medicina. Mexicali, México; Unidad de Trasplante Dr. Abraham Sumoza, Valencia, Venezuela; Hospital Central. Instituto de Previsión Social, Asunción, Paraguay; Hospital Pequeño Principe, Curitiba, Brazil; Hospital Británico, Montevideo Uruguay; Favaloro, University Hospital, Buenos Aires, Argentina; ITAC, Buenos Aires, Argentina; Instituto de Cancerología, Las Américas, Medellín, Colombia.

Andrés Gómez-De León (AG)

Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González. Monterrey, México; Hospital de Clínicas, Curitiba, Brazil; Universidad Autónoma de Baja California, Facultad de Medicina. Mexicali, México; Unidad de Trasplante Dr. Abraham Sumoza, Valencia, Venezuela; Hospital Central. Instituto de Previsión Social, Asunción, Paraguay; Hospital Pequeño Principe, Curitiba, Brazil; Hospital Británico, Montevideo Uruguay; Favaloro, University Hospital, Buenos Aires, Argentina; ITAC, Buenos Aires, Argentina; Instituto de Cancerología, Las Américas, Medellín, Colombia. Electronic address: drgomezdeleon@gmail.com.
Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario Dr. José Eleuterio González. Monterrey, México; Hospital de Clínicas, Curitiba, Brazil; Universidad Autónoma de Baja California, Facultad de Medicina. Mexicali, México; Unidad de Trasplante Dr. Abraham Sumoza, Valencia, Venezuela; Hospital Central. Instituto de Previsión Social, Asunción, Paraguay; Hospital Pequeño Principe, Curitiba, Brazil; Hospital Británico, Montevideo Uruguay; Favaloro, University Hospital, Buenos Aires, Argentina; ITAC, Buenos Aires, Argentina; Instituto de Cancerología, Las Américas, Medellín, Colombia.

Classifications MeSH